Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

INTRODUCTION: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week results from CLARITY, a second head-to-head trial comparing secukinumab wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagel, Jerry, Nia, John, Hashim, Peter W., Patekar, Manmath, de Vera, Ana, Hugot, Sophie, Sheng, Kuan, Xia, Summer, Gilloteau, Isabelle, Muscianisi, Elisa, Blauvelt, Andrew, Lebwohl, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261116/
https://www.ncbi.nlm.nih.gov/pubmed/30334147
http://dx.doi.org/10.1007/s13555-018-0265-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261116/
https://www.ncbi.nlm.nih.gov/pubmed/30334147
http://dx.doi.org/10.1007/s13555-018-0265-y

Ejemplares similares